Bio-Thera And Biomm Widen Biosimilar Alliance In Brazil
Pair Previously Allied On Chinese Firm’s Proposed Avastin Biosimilar
China’s Bio-Thera Solutions is continuing to pen deals offloading commercialization rights outside of its domestic market to for its BAT2206 biosimilar Stelara (ustekinumab) candidate, this time with Biomm in Brazil.
